Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 versus investigator’s choice chemotherapy in previously treated advanced or metastatic urothelial carcinoma
2024-520014-22-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Planned start Apr 2026; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-520014-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520014-22-00.